Page 7 - ஜேன் பஜ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category

PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category - New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 - News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., Jan. 14, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advocacy organizations around the world who are committed to developing innovative and sustaining programs that help address the unmet needs of the rare disease community. This year, a new entry category dedicated to supporting programs that focus on the transition of those living with Duchenne from adolescence to adulthood has been introduced.

Lucia oliveiraMary frances harmonJane bajMuscular dystrophy associationHope through researchTherapeutics incNational institute of neurological disordersSenior vice presidentCorporate relationsRealize innovationParent project muscularMore informationDuchenne muscular dystrophyNeurological disordersMuscular dystrophyHope through

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate.

Jane bajTherapeutics incCompensation committeePtc therapeuticsHealth care amp hospitalsMedical pharmaceuticalsஜேன் பஜ்சிகிச்சை இன்க்இழப்பீடு குழுட சிகிச்சைஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள்மருத்துவ மருந்துகள்உயிரி தொழில்நுட்பவியல்

PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J P Morgan Healthcare Conference

Share this article Share this article SOUTH PLAINFIELD, N.J., Jan. 11, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39 th Annual J.P. Morgan Healthcare Conference today, Monday, Jan. 11 at 7:30 a.m. EST. Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2020 accomplishments and highlight upcoming potential value-creating milestones. Preliminary 2020 unaudited financial results and 2021 financial guidance will also be provided. The presentation will be webcast live on the Events and Presentations page of the Investors section of PTC Therapeutics website at www.ptcbio.com.

United statesStuartw peltzJane bajTherapeutics incHealthcare conferenceChief executive officerSpinal muscular atrophyEuropean medicines agencyMedicinal productsHuman useJapanese new drug applicationValue creating milestonesBiologics license applicationDiffuse intrinsic pontine gliomaFull yearMore information

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Lisa hayesJane bajCompensation committee onTherapeutics incலிசா வைக்கோல்ஜேன் பஜ்இழப்பீடு குழு ஆன்சிகிச்சை இன்க்

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., Dec. 18, 2020 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an aggregate of 12,500 shares of its common stock and 4,360 restricted stock units ( RSUs ), each representing the right to receive one share of its common stock upon vesting, to 10 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires employment compensation. The inducement grants were approved by PTC s Compensation Committee on December 15, 2020 and are being made as an inducement material to each employee s acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

Lisa hayesJane bajCompensation committee onTherapeutics incலிசா வைக்கோல்ஜேன் பஜ்இழப்பீடு குழு ஆன்சிகிச்சை இன்க்